{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 46,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/15",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "The Adalimumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1f0dd55-22a9-4478-844e-31ed0bba5b25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "AN Count reductions most profound in moderate and severe patients; Highly competitive HiSCR response rates continued to improve after cessation of dosing; Pain and pruritus response rates and reductions significantly higher than placebo and SOC benchmarks; Physician Global Assessment (PGA) scores improved in 5 of 12 patients, including 1 moderate disease patient with full disease clearance, and stable in the others",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b0f5197-bda5-47c5-ae60-31f8a4b5fd57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "table",
      "text": "Comparison table of KT-474 vs Placebo vs Adalimumab across metrics like AN Count, HiSCR50/75, and Pain NRS30",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5399881-2ea5-4a71-b1fa-0b283a42860a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-474 Showed Meaningful Signs of Clinical Activity in HS, Comparing Favorably to Placebo Benchmarks and SOC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2f8af90-8649-40a5-995d-59f3f1149f08",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "8556caaf-0b4f-487d-9c9e-9ad5e4d49632",
      "evidence": "Direct comparison of clinical trial data against external benchmarks",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "3821b163-197d-4c86-9367-33b4bd3fb93a",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck showcases the potential for broad activity across multiple diseases, creating desire for Kymera's TPD approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7b376215-a5b5-4891-ad20-1901edfeffd7",
      "evidence": "The deck presents a clear logical chain from the problem to the solution and potential benefits.",
      "position": 0,
      "objective": "To demonstrate the logic and potential of Kymera's TPD approach",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4c55e1a3-cbe4-4bd4-91f4-d237841a6ee0",
      "evidence": "The deck implies the limitations of current treatments and the potential consequences of not adopting new approaches.",
      "position": 1,
      "objective": "To highlight the cost of inaction and the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}